Hollandt Jan H, Mahlerwein Malte
Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Germany.
Sleep Breath. 2003 Jun;7(2):87-94. doi: 10.1007/s11325-003-0087-7.
Although nasal continuous positive airway pressure (nCPAP) treatment is the most efficient therapy for obstructive sleep apnea (OSA), compliance with therapy is poor because of several side effects. Among these adverse effects some are related to the reactions of the nose to nCPAP which are briefly described. In a long-term survey of 109 OSA patients, 80.6% continued nCPAP for at least 3 years until the last follow-up. Follow-up ranged between 0.8 and 109 months with a mean time of 43 (SD +/- 24.7) months. Among all patients treated with nCPAP, only 46.6% met our criteria for long-term compliance, defined as a mean use of the CPAP machine for at least 5 hours per night. Within the objective measures such as age, body mass index, neck circumference, nasal airflow, apnea-hypopnea index, minimal oxygen saturation, and level of nCPAP pressure, no predictive factor for daily use of nCPAP could be found. However, pretherapeutic daytime somnolence (measured by visual analogue scale and Epworth Sleepiness Scale) and its improvement obtained from the therapy showed a significant effect on the daily use of the CPAP machine.
尽管鼻持续气道正压通气(nCPAP)治疗是阻塞性睡眠呼吸暂停(OSA)最有效的治疗方法,但由于多种副作用,治疗依从性较差。在这些不良反应中,有些与鼻子对nCPAP的反应有关,在此简要描述。在一项对109例OSA患者的长期调查中,80.6%的患者持续使用nCPAP至少3年直至最后一次随访。随访时间为0.8至109个月,平均时间为43(标准差±24.7)个月。在所有接受nCPAP治疗的患者中,只有46.6%符合我们的长期依从性标准,即CPAP机器每晚平均使用至少5小时。在年龄、体重指数、颈围、鼻气流、呼吸暂停低通气指数、最低氧饱和度和nCPAP压力水平等客观指标中,未发现nCPAP每日使用的预测因素。然而,治疗前的日间嗜睡(通过视觉模拟量表和爱泼华嗜睡量表测量)及其从治疗中获得的改善对CPAP机器的每日使用有显著影响。